Draft:Bioneer Corporation
 | Review waiting, please be patient.
This may take 2–3 weeks or more, since drafts are reviewed in no specific order. There are 651 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Submission declined on 7 July 2025 by MediaKyle (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
 | |
 The Bioneer Global Center, the current headquarters of Bioneer Corporation, located in Daejeon, South Korea. | |
| Company type | Public |
|---|---|
| KOSDAQ: 064550 | |
| Industry | Biotechnology, Life Sciences |
| Founded | 1992 |
| Founder | Han-Oh Park |
| Headquarters | Daejeon , South Korea |
Key people | Han-Oh Park (CEO, Chairman) |
| Products | Life Sciences, Molecular diagnostics, RNAi therapeutics, cosmeceuticals, probiotics |
| Revenue | KRW 294.0 billion (2024) |
| KRW 2.8 billion (2024) | |
| Subsidiaries |
|
| Website | www.bioneer.com |
Bioneer Corporation is a biotechnology company based in Daejeon, South Korea. Established in 1992, the company is listed on the KOSDAQ stock exchange.[1][2]
The company develops and manufactures life sciences, molecular diagnostics,[3] RNAi therapeutics,[4] cosmeceuticals,[5] [6] and probiotics,[7][8] serving both domestic and global markets.
History
[edit]1992–1999: Foundation and Early Development
[edit]
-1992: The company was founded as "Hanguk Saenggong" (Korean: 한국생공) in Daejeon, South Korea, as a spin-off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB).[9] Recognized as Korea’s first bio-venture company,[10] it initially focused on the development and supply of PCR enzymes and primers (synthetic DNA) for life sciences research.[11]
- 1996: The company renamed itself Bioneer (Korean: 바이오니아) as a portmanteau of "bio-engineering" and "bio-pioneering," reflecting its mission to innovate at the frontier of biotechnology.[10]
- 1990s: The company began supplying synthetic DNA oligonucleotides, PCR reagents, and other molecular biology products, including sequencing services, genetic extraction and analysis instruments, and microbial culture equipment.[11][12][13]These products and services were widely adopted in Korean life science research.[14][15]
2000–2016: Platform Expansion and Globalization
[edit]
- 2001: Bioneer acquired a large-scale manufacturing facility in Daejeon and installed mass-production synthesizers, including a high-throughput 384-well parallel oligonucleotide synthesizer developed in 2000.[13] [16] This expansion significantly increased the company's industrial capacity for nucleic acid manufacturing, enabling large-scale independent production of synthetic DNA to support molecular diagnostics and RNA-based drug development.
- 2005: The company was listed on the KOSDAQ stock exchange.[17]
- 2006: Bioneer registered the AccuOligo® patent (South Korea Patent No. 10-0777249), a technology designed to prevent oligonucleotide loss during handling and transport.[18]
- Late 2000s: Drawing inspiration from the vertically integrated structure of global healthcare firms such as Roche, Bioneer began independently researching, developing, and manufacturing the core materials, components, and instruments required for molecular diagnostics and siRNA-based drug development.[3][19]
- 2009: During the H1N1 influenza pandemic, Bioneer increased production of molecular diagnostic kits and equipment to meet higher demand, supplying major hospitals and clinical laboratories in South Korea.[20]
- 2010: Bioneer participated in a collaborative research project with the Korea Research Institute of Bioscience and Biotechnology (KRIBB), the UK’s Imperial Cancer Research Fund (now Cancer Research UK), and Sir Paul Nurse. Bioneer supplied custom oligonucleotides and contributed to the construction of a genome-wide gene deletion library for fission yeast (Schizosaccharomyces pombe), covering over 98% of its protein-coding genes. This resource enabled two landmark studies published in Nature Biotechnology that identified essential genes for cell division, cell shape, and viability, establishing Bioneer as a key contributor to functional genomics in eukaryotes.[21]
- 2013: Bioneer expanded its molecular diagnostics portfolio after receiving regulatory approval for 21 products from the Korean Ministry of Food and Drug Safety (MFDS).[22]
- 2014: Bioneer filed a U.S. patent application for the SAMiRNA (Self-Assembled-Micelle inhibitory RNA) platform, an RNAi delivery technology.[23]
- 2014: The probiotic strain Lactobacillus gasseri BNR17 ((BNR17, hereafter) was approved by the Korean Ministry of Food and Drug Safety (MFDS) as a functional ingredient for reducing body fat.[24]
- 2016: Bioneer’s AccuPower ZIKV (DENV, CHIKV) Multiplex Real-Time RT-PCR Kit was lited by the World Health Organization (WHO)for emergency use in global public health responses.[25][26][27]
2017–present: Expansion as a Comprehensive Healthcare Company
[edit]Starting in 2017, Bioneer broadened its business portfolio in the healthcare sector by enhancing molecular diagnostics platform, advancing RNAi therapies through its subsidiary siRNAgen Therapeutics, launching the RNAi-based cosmeceutical product CosmeRNA, and developing the microbiome-based solutions through AceBiome, including the commercialization of the probiotic strain BNR17.[28][29] [30]
- 2017: AceBiome was established as a subsidiary focused on the commercialization of the probiotic strain BNR17, as well as the health functional food (probiotics) business.[8]
- 2018: AceBiome entered into a licensing agreement with UAS Labs, enabling the U.S.-based company to manufacture and commercialize BNR17 in North America and other global markets.[7] In the same year, BNR17 received the NutraIngredients-USA Award for Weight Management Ingredient.[31]
- After 2018: UAS Labs was acquired by Danish bioscience company Chr. Hansen in 2020. Chr. Hansen subsequently merged with Novozymes to form Novonesis in 2024. Through this succession of partnerships and corporate mergers, BNR17 has continued to be distributed internationally as part of the expanded biotech portfolio of Novonesis.
- 2019: Bioneer established the subsidiary siRNAgen Therapeutics to advance drug development using the SAMiRNA platform, focusing on RNAi-based therapies for chronic and intractable diseases.[32][33]
- During the COVID-19 pandemic, Bioneer supplied molecular diagnostic instruments and kits to more than 90 countries, supporting global testing and surveillance efforts.[34][35][36] [37]
- In 2022, AceBiome received the IR52 Jang Young-Shil Award for BNR17.[38]
- In 2023, Bioneer launched CosmeRNA[6], a topical RNA interference-based cosmetic tonic developed using its proprietary SAMiRNA (Self-Assembled-Micelle inhibitory RNA) technology. Intended to help alleviate symptoms of androgenetic alopecia (AGA), CosmeRNA modulates androgen receptor activity linked to hair loss. The SAMiRNA platform forms stable nanoparticles with enhanced skin penetration and low immunogenicity, allowing for weekly topical application without systemic absorption. Its cosmetic efficacy was evaluated in a clinical study published in Scientific Reports[39], and the technology was reviewed in a 2024 article in EMJ Dermatology discussing RNAi-based approaches for aesthetic dermatology.[40]
- In 2024, CosmeRNA received an award in the Hair Products category at Cosmoprof Worldwide Bologna.[41]
- In 2024, Bioneer’s HIV-1 quantitative RT-PCR kit received WHO prequalification, enabling its use in international procurement channels for HIV diagnostics.[42]
- In 2024, siRNAgen Therapeutics completed a phase 1a clinical trial of SRN-001, an siRNA-based candidate for fibrosis, in Australia.[43] [44]
- Bioneer has partnered with organizations such as the Foundation for Innovative New Diagnostics (FIND), Médecins Sans Frontières (MSF), and the RIGHT Foundation to improve access to molecular diagnostics for infectious diseases in resource-limited settings through joint development and clinical evaluation.[45][46][47]
Subsidiaries
[edit]- siRNAgen Therapeutics: Focuses on RNA interference (RNAi) therapeutics, including the SAMiRNA platform.
- AceBiome: Specializes in probiotics, including the commercialization of the BNR17 strain.
Awards and recognition
[edit]| Year | Award/Recognition | Recipient/Division | Details | Reference |
|---|---|---|---|---|
| 2015 | K-BrainPower (Outstanding Brainpower Company) Selection | Bioneer | Ministry of Trade, Industry and Energy | [48] |
| 2017 | Excellent Technology Research Center (ATC) Designation | Bioneer | Ministry of Trade, Industry and Energy | [49] |
| 2018 | NutraIngredients-USA Award, Weight Management Ingredient | AceBiome (BNR17) | NutraIngredients-USA | [31] |
| 2020 | Innovative Medical Device Company Certification | Bioneer | Ministry of Health and Welfare | [30] |
| 2020 | National Representative 1000 Innovative Companies Selection | Bioneer | Ministry of Trade, Industry and Energy | [50] |
| 2021 | Global Small Giant Company Selection | Bioneer | Ministry of SMEs and Startups | [51] |
| 2021 | 100 Million Dollar Export Tower Award | Bioneer | Ministry of Trade, Industry and Energy | [52] |
| 2022 | IR52 Jang Young-Shil Award | AceBiome (BNR17) | Ministry of Science and ICT | [38] |
| 2022 | Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow | siRNAgen Therapeutics | Johnson & Johnson Innovation, Janssen Korea | [53] |
| 2023 | Innovative Medical Device Company – Leading Innovation Type Certification | Bioneer | Ministry of Health and Welfare | [54] |
| 2024 | Cosmoprof Award, Hair Products category | Bioneer (CosmeRNA) | Cosmoprof Worldwide Bologna | [41] |
References
[edit]- ^ "Bioneer Corporation Company Profile - South Korea". EMIS. Retrieved 2025-07-02.
- ^ "Bioneer Corporation - Daejeon, Korea". Bionity. Retrieved 2025-07-02.
- ^ a b "Bioneer Develops Ebola MDx Kit in Partnership with Nigerian Biotech Agency". GenomeWeb. 2014-08-28. Retrieved 2025-07-08.
- ^ "Bioneer accelerates RNAi drug development". BioSpectator. 2018-08-20. Retrieved 2025-07-02.
- ^ "CosmeRNA: Europe's $330 Hair Loss Breakthrough". Medical Channel Asia. 2023-06-06. Retrieved 2025-07-02.
- ^ a b "Bioneer to launch CosmeRNA in Europe via Amazon". Health Korea News. 2023-04-04. Retrieved 2025-07-02.
- ^ a b "UAS Labs Announces Licensing Agreement with AceBiome". Microbiome Times. 2018-07-18. Retrieved 2025-07-02.
- ^ a b "About AceBiome". Ingredients Network. Retrieved 2025-07-02.
- ^ "[혁신창업의 길] 한국 바이오벤처 1호, 글로벌 강소기업 되다". 중앙일보. 2021-11-25. Retrieved 2025-07-08.
- ^ a b "한국 바이오벤처의 태동과 성장". STEPI (in Korean). 과학기술정책연구원. 2013-12-31. Retrieved 2025-07-08.
- ^ a b >"내열성 DNA 중합효소 및 수식효소의 산업화 연구". BioIN. 1999-12-01. Retrieved 2025-07-08.
- ^ "Bioneer Company Profile". PharmaBoardroom. 2024. Retrieved 2025-07-08.
- ^ a b "바이오니아 2001년 사업보고서". DART (in Korean). 금융감독원. 2001-12-28. Retrieved 2025-07-08.
- ^ 이용수 (1996). "미세입자를 사용하여 DNA를 도입하는 저가의 식물세포 형질전환 장치". Journal of Plant Biotechnology (in Korean). 23 (1): 51–54. Retrieved 2025-07-08.
- ^ 안지영 외 (1999). "Methicillin 내성 포도구균의 mecI, mecA 및 femA 유전자에 관한 연구" (PDF). 대한임상병리학회지 (in Korean). 19 (1): 62–69. Retrieved 2025-07-08.
- ^ "유전자, 조작 넘어 인공으로 만든다". 한겨레 (in Korean). 2009-12-15. Retrieved 2025-07-08.
- ^ "바이오니아 신규상장(코스닥) 공시". 전자공시시스템(DART). Retrieved 2025-07-14.
- ^ "건조 올리고뉴클레오티드 조성물" (PDF). KIPO (in Korean). 2006-07-12. Retrieved 2025-07-08.
- ^ "바이오 업계도 '소부장' 국산화 움직임…주목받는 바이오니아". 매일경제 (in Korean). 2020-07-28. Retrieved 2025-07-08.
- ^ "신종플루 덕(?)…특수 누리는 대덕특구 벤처". 디지털타임스 (in Korean). 2009-11-09. Retrieved 2025-07-08.
- ^ Kim, D. U.; et al. (2010). "Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe". Nature Biotechnology. 28 (6): 617–623. doi:10.1038/nbt.1628. PMC 3962850. PMID 20473289.
- ^ "바이오니아, 감염성 질병진단 검사 21개 품목 식약청 허가 획득". WOW TV (in Korean). 2013-01-07. Retrieved 2025-07-08.
- ^ "US9326941B2: High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same". Google Patents. USPTO. 2016-05-03. Retrieved 2025-07-08.
- ^ "기능성 농식품자원 정보 - Lactobacillus gasseri BNR17". 기능성 농식품자원 정보서비스 (in Korean). 농림축산식품부. 2014. Retrieved 2025-07-11.
- ^ "WHO Emergency Use Listing for In vitro diagnostics (IVDs) for Zika Virus". WHO. 2025-03-21. Retrieved 2025-07-03.
- ^ "AccuPower® ZIKV (DENV, CHIKV) Multiplex Real-Time RT-PCR Kit" (PDF). WHO. Retrieved 2025-07-03.
- ^ "Bioneer Zika Detection Kit Eligible for WHO Procurement". 360Dx. 3 November 2016. Retrieved 2025-07-03.
- ^ "에이스바이옴, 기능성 프로바이오틱스 시장 선도…'현대인 건강' 지킴이". MBN. 2025-04-03. Retrieved 2025-07-14.
- ^ "대덕 진단키트, 23조 LNG선 100척 수주 '나비효과'?". 헬로디디. Retrieved 2025-07-14.
- ^ a b "바이오니아, 혁신의료기기기업 인증". 메디칼타임즈 (in Korean). 2020-12-28. Retrieved 2025-07-08.
- ^ a b "MEET THE WINNERS: Ingredients of the Year". NutraIngredients-USA. 2018-07-25. Retrieved 2025-07-02.
- ^ "바이오니아 2020년 사업보고서" (PDF). 바이오니아. 2021-03-19. Retrieved 2025-07-14.
- ^ "siRNAgen Therapeutics". CB Insights. Retrieved 2025-07-14.
- ^ "Bioneer to export COVID-19 diagnostic kits to Romania". Korea IT Times. 2020-03-19.
- ^ "Korea's exports of virus test kits tipped to grow further". Yonhap News Agency. 2020-05-21.
- ^ AccuPower RV1 RT-PCR Kit clinical evaluation report, KISTI ScienceON, 2021-05. https://scienceon.kisti.re.kr/srch/selectPORSrchReport.do?cn=TRKO202200008988
- ^ Suh, I. B.; Lim, J.; Kim, H. S.; Rhim, G.; Kim, H.; Kim, H.; Lee, S. M.; Park, H. S.; Song, H. J.; Hong, M.; Shin, G. S.; Kim, M. J. (2022-02-10). "Development and Evaluation of AccuPower COVID-19 Multiplex Real-Time RT-PCR Kit". PLOS ONE. 17 (2): e0263341. doi:10.1371/journal.pone.0263341. PMC 8830688. PMID 35143538.
- ^ a b "장영실상 수상". Maeil Business Newspaper. 2022-03-22. Retrieved 2025-07-14.
- ^ "Protective effect of SAMiRNA-AREG in a murine model of bleomycin-induced pulmonary fibrosis". Scientific Reports. 2022. doi:10.1038/s41598-022-05544-w.
- ^ "Current Landscape and Emerging Therapies in Hair Loss Treatment for Androgenetic Alopecia". EMJ Dermatology. 12: 67–74. 2024.
- ^ a b "CosmeRNA Anti-Hair Loss Tonic wins Bioneer Corp. (South Korea) – Cosmoprof Worldwide Bologna, 2024" (PDF). Cosmoprof Awards. Retrieved 2025-07-03.
- ^ "AccuPower HIV-1 Quantitative RT-PCR Kit" (PDF). WHO. 2024-09-10. Retrieved 2025-07-03.
- ^ "A Phase 1 Study of SAMiRNA-AREG in Healthy Adults". ClinicalTrials.gov. U.S. National Library of Medicine. Retrieved 2025-07-15.
- ^ Lee Sang-gyu (2024-06-25). "Bioneer marks milestone with phase 1a clinical results of SRN-001, a next-generation new drug candidate". Maeil Business Newspaper (MK). Retrieved 2025-07-14.
SRN-001 is the first case where Bioneer's SAMiRNA platform was applied to humans.
- ^ "US$21 million investment brings molecular diagnostic testing for COVID-19 and other infectious diseases closer to patients in low- and middle-income countries". FIND. 2021-07-29. Retrieved 2025-07-03.
- ^ "Global Health Technology Research Fund "RIGHT Fund"". International Tuberculosis Research Center. 2020-03-12. Retrieved 2025-07-03.
- ^ "Bioneer showcases IRON-qPCR™ and RFIA kits at 2024 World Conference on Lung Health". Maeil Business Newspaper. 2024-11-19. Retrieved 2025-07-02.
- ^ "바이오니아, 산업부 'K-브레인파워' 기업 선정". 아시아경제 (in Korean). 2015-09-08. Retrieved 2025-07-07.
- ^ "2017년 ATC(우수기술연구센터) 지정서 수여식 개최". 대한민국 정책브리핑 (in Korean). 2017-07-10. Retrieved 2025-07-07.
- ^ "혁신기업 국가대표 1000 선정 계획 발표". 대한민국 정책브리핑 (in Korean). 대한민국 정부. 2020-11-06. Retrieved 2025-07-15.
- ^ "2021 Global Small Giant Company Selection". Ministry of SMEs and Startups. 2021-05-10. Retrieved 2025-07-03.
- ^ "The 58th Trade Day Event and Export Tower Awardees". Korea Policy Briefing. 2021-12-06. Retrieved 2025-07-14.
- ^ "Johnson & Johnson Innovation LLC and Janssen Korea Ltd. Announce Awardees of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow". Johnson & Johnson Innovation. 2022-09-28. Retrieved 2025-07-03.
- ^ "바이오니아, 혁신의료기기기업 인증". 의학신문 (in Korean). 2023-12-28. Retrieved 2025-07-07.